Collaboration forms the cornerstone of the MedChem Australia model, fostering partnerships that empower your research to reach its full translation potential.

Our default IP ownership model is:

• the Project Provider is commercialisation lead
• newly created Project IP jointly owned by the parties
• shared benefits negotiated

As the Project Provider and the allocated MedChem Australia Node will be joint contributors to the creation of new intellectual property (IP), newly created Project IP will be owned jointly by the parties. Shared benefits (e.g revenue share) will also be negotiated. The Project Provider is expected to be the commercialisation lead.

MedChem Australia appreciates that, depending on circumstances, a joint IP ownership model may not be feasible. Under such circumstances, applicants may negotiate changes to the default IP model, on a case-by-case basis. As MedChem Australia is not a separate legal entity, the formal contractual arrangements will be entered into between the successful applicant’s organisation and the MedChem Australia Node that the project has been allocated to.